Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132633) titled 'A prospective phase II clinical trial to evaluate the efficacy and safety of irinotecan liposome combined with PD-L1 inhibitor in the second-line treatment of large cell neuroendocrine carcinoma of the lung' on Sept. 16.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Cancer Hospital Chinese Academy of Medical Sciences
Condition:
Large cell neuroendocrine carcinoma of the lung
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-10-01
Target Sample Size: Experimental group:30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.or...